U.S. settles 'pay-for-delay' fight with drugmaker Teva over Provigil
WASHINGTON (Reuters) - U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit tied to wakefulness drug Provigil, the Federal Trade Commission said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - May 28, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Teva to lay out $512M to settle pay-to-delay lawsuit
Teva Pharmaceutical Industries Ltd. will pay $512 million to resolve litigation alleging Cephalon — a Chester County biotechnology company Teva bought in 2011 for $6.8 billion — improperly delayed the launch of generic versions of its flagship sleep disorder drug Provigil.
A report by Reuters said the proposed settlement is the largest ever to be paid to drug wholesalers and retailers over allegations of delaying generic drugs.
The settlement agreement must still be approved by Judge Mitchell… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 21, 2015 Category: Biotechnology Authors: John George Source Type: news
Teva to pay $512 million to settle claims of delayed generic Provigil
(Reuters) - Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc, which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil. (Source: Reuters: Health)
Source: Reuters: Health - April 20, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Teva to pay $512 million to settle claims of delayed generic Provigil
(Reuters) - Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc, which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil, according to court papers. (Source: Reuters: Health)
Source: Reuters: Health - April 20, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Experts Weigh In On The Ethics Of Using Brain-Enhancing Drugs
By: Tanya Lewis
Published: March 26, 2015 08:00am ET
Boosting a person's smarts through drugs or electrical or magnetic stimulation of the brain is becoming an increasingly widespread practice. Now, bioethicists are weighing in, saying that while such cognitive enhancement is neither bad nor good, it deserves more research.
In the past, "there have been many arguments that suggest one should take an ethical stance for or against cognitive enhancement" of healthy individuals, said Amy Gutmann, chairwoman of the Presidential Commission for the Study of Bioethical Issues, which released the second part of a report...
Source: Science - The Huffington Post - March 27, 2015 Category: Science Source Type: news
Could modafinil be a drug of dependence? - Dhillon R, Wu X, Bastiampillai T, Tibrewal P.
[Abstract unavailable]
Language: en... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - January 23, 2015 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
Letter: Modafinil and Sleep Disorders
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - December 1, 2014 Category: Emergency Medicine Tags: Letter Source Type: news
Are Modafinil's Brain-Boosting Benefits Hype Or Science?
Modafinil has been approved for treatment of narcolepsy, but it's often used to improve mental performance. The question is, does it work? A new study says probably not.» E-Mail This (Source: NPR Health and Science)
Source: NPR Health and Science - November 17, 2014 Category: Consumer Health News Authors: Maanvi Singh Source Type: news
'Smart drug' modafinil may not make you brainier
Conclusion
Modafinil is reported to be frequently used outside of its licensed indication (treatment of narcolepsy) to enhance cognitive performance. This study has cast doubt upon these supposed effects. In this RCT, modafinil slowed responses while having no effect on the accuracy of performance on the Hayling Sentence Completion Test.
The exact way modafinil promotes wakefulness is not fully understood. The Hayling Sentence Completion Test is only one measure of cognitive function, and it may be that modafinil has different effects on the performance of different tests. For example, modafinil has been a way to aid conce...
Source: NHS News Feed - November 13, 2014 Category: Consumer Health News Tags: Medication Neurology Source Type: news
‘Smart’ drugs won’t make smart people smarter, research concludes
It is claimed one in five students have taken the ‘smart’ drug Modafinil to boost their ability to study and improve their chances of exam success. But new research into the effects of Modafinil has shown that healthy students could find their performance impaired by the drug. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 12, 2014 Category: Science Source Type: news
'Smart' drugs won't make smart people smarter
(University of Nottingham) It is claimed one in five students have taken the 'smart' drug Modafinil to boost their ability to study and improve their chances of exam success. But new research into the effects of Modafinil has shown that healthy students could find their performance impaired by the drug. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - November 12, 2014 Category: Global & Universal Source Type: news
Modafinil in Early Pregnancy Not Tied to Congenital Malformations
Large birth registry study conducted in Norway and Sweden did not show link to major malformations (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 11, 2014 Category: Psychiatry Tags: Gynecology, Neurology, Nursing, Pediatrics, Pharmacy, Psychiatry, Journal, Source Type: news
Modafinil Fails to Improve Fatigue in Cancer PatientsModafinil Fails to Improve Fatigue in Cancer Patients
Modafinil led to a clinically significant improvement in fatigue scores, but there was no significant difference from that seen with placebo. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 8, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Drug Flunks Test in Cancer-Related Fatigue
(MedPage Today) -- Cancer-related fatigue failed to improve significantly in patients treated with the alertness-promoting drug modafinil, British investigators reported. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 30, 2014 Category: Hematology Source Type: news
Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial - Philip P, Chaufton C, Taillard J, Capelli A, Coste O, Leger D, Moore N, Sagaspe P.
STUDY OBJECTIVE: Patients with excessive daytime sleepiness (EDS) are at high risk for driving accidents, and physicians are concerned by the effect of alerting drugs on driving skills of sleepy patients. No study has up to now investigated the effect of m... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 24, 2014 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
